Influenza A Virus H5N1 Subtype Infections-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Influenza A Virus H5N1 Subtype Infections-Pipeline Review H2 2017” this Report provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.
(EMAILWIRE.COM, September 22, 2017 ) H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 11, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.
Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/influenza-a-virus-h5n1-subtype-infections-pipeline-review-h2-2017
Report Scope
-The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
-The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)
Request a sample copy at http://www.reportsweb.com/inquiry&RW00011060442/sample
Reasons to buy
-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Akshaya Bio Inc
Altimmune Inc
Antigen Express Inc
Aphios Corp
BiondVax Pharmaceuticals Ltd
CEL-SCI Corp
Cocrystal Pharma Inc
Curevac AG
Gemmus Pharma Inc
GlaxoSmithKline Plc
Hemispherx Biopharma Inc
iBio Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Kineta Inc
Lakewood-Amedex Inc
Medicago Inc
Medigen Vaccine Biologics Corp
Microbiotix Inc
NanoBio Corp
Nanotherapeutics Inc
NanoViricides Inc
OPKO Health Inc
PaxVax Inc
PeptiDream Inc
Shionogi & Co Ltd
Takeda Pharmaceutical Company Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW00011060442/discount
List of Tables
Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Akshaya Bio Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Altimmune Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Antigen Express Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Aphios Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by CEL-SCI Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Cocrystal Pharma Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Curevac AG, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Gemmus Pharma Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by GlaxoSmithKline Plc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Hemispherx Biopharma Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by iBio Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Johnson & Johnson, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Kineta Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Lakewood-Amedex Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Medicago Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Medigen Vaccine Biologics Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Microbiotix Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by NanoBio Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Nanotherapeutics Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by NanoViricides Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by OPKO Health Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by PaxVax Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by PeptiDream Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Shionogi & Co Ltd, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW00011060442/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 11, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.
Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/influenza-a-virus-h5n1-subtype-infections-pipeline-review-h2-2017
Report Scope
-The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
-The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)
Request a sample copy at http://www.reportsweb.com/inquiry&RW00011060442/sample
Reasons to buy
-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Akshaya Bio Inc
Altimmune Inc
Antigen Express Inc
Aphios Corp
BiondVax Pharmaceuticals Ltd
CEL-SCI Corp
Cocrystal Pharma Inc
Curevac AG
Gemmus Pharma Inc
GlaxoSmithKline Plc
Hemispherx Biopharma Inc
iBio Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Kineta Inc
Lakewood-Amedex Inc
Medicago Inc
Medigen Vaccine Biologics Corp
Microbiotix Inc
NanoBio Corp
Nanotherapeutics Inc
NanoViricides Inc
OPKO Health Inc
PaxVax Inc
PeptiDream Inc
Shionogi & Co Ltd
Takeda Pharmaceutical Company Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW00011060442/discount
List of Tables
Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Akshaya Bio Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Altimmune Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Antigen Express Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Aphios Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by CEL-SCI Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Cocrystal Pharma Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Curevac AG, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Gemmus Pharma Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by GlaxoSmithKline Plc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Hemispherx Biopharma Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by iBio Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Johnson & Johnson, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Kineta Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Lakewood-Amedex Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Medicago Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Medigen Vaccine Biologics Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Microbiotix Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by NanoBio Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Nanotherapeutics Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by NanoViricides Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by OPKO Health Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by PaxVax Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by PeptiDream Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Shionogi & Co Ltd, H2 2017
Influenza A Virus, H5N1 Subtype Infections-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW00011060442/buy/2000
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results